Table 1.
Clinical Data of Patients Undergoing Both Studies
| Invasive Study (n=9) | Noninvasive Study (n=190) | |
|---|---|---|
| Age | 66±7 | 67± 3 |
| Sex, male/female | 8/1 | 151/39 |
| Ischemic/nonischemic | 6/3 | 135/55 |
| NYHA I | – | 18 |
| NYHA II | 2 | 81 |
| NYHA III | 7 | 91 |
| NYHA IV | – | – |
| SAP, mm Hg | 112±16 | 118±26 |
| DAP, mm Hg | 67±10 | 71±8 |
| HR, bpm | 66±12 | 68±10 |
| EF, % | 30±5 | 32±7 |
| PAP, mm Hg | 47±14 | 48±11 |
| Moderate to severe mitral regurgitation | 4 (48%) | 24 (46%) |
| BNP, pg/mL | 475.0±49.3 | 403.5±69.7 |
| Therapy (% of patients) | ||
| ACE inhibitors and/or ATII inhibitors | 100% | 85% |
| β-blockers | 72% | 84% |
| Amiodarone | 54% | 60% |
| Diuretics | 100% | 90% |
| Others (digoxin, ivabradine) | 2% | 6% |
| ICD and/or ICD+CRT | 72% | 69% |
Data are expressed as mean±1 SD except as noted. ACE indicates angiotensin-converting enzyme; ATII, angiotensin II; BNP indicates brain natriuretic peptide; CRT, cardiac resynchronization therapy; DAP, diastolic arterial pressure; EF, ejection fraction; HR, heart rate; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart Association classification; PAP, estimated pulmonary arterial pressure; SAP, systolic arterial pressure.